<email obscured>> wrote:
> Hi!
>
> I would be interested in this virtual lab meeting.
>
> Best,
>
> Thierry Le Bihan, Ph.D.
> Senior Research Scientist
> <email obscured>
> 1-855-899-9990 ext 705
> Unit 450, 137 Glasgow St
> Kitchener, ON, Canada N2G 4X8
>
> *Rapid Novor, Inc β Kitchener β N2G 4X8 β ON β Canada β www.rapidnovor.com
> <http://www.rapidnovor.com/>*
> *This electronic message contains information from Rapid Novor, Inc. The
> contents may be privileged and confidential and are intended for the use of
> the intended addressee(s) only. If you are not an intended addressee, note
> that any disclosure, copying, distribution, or use of the contents of this
> message is prohibited. If you have received this e-mail in error, please
> notify the sender immediately and delete this email. Thank you.*
>
>
>
> ---------- Forwarded message ---------
> From: David Blum <email obscured>>
> Date: Mon, Jun 29, 2020 at 2:30 PM
> Subject: Re: [ABRF Ab Forum] FW: [EXT] Re: [core rigor and reproducibility
> (corre)] We have an RRID number
> To: <email obscured>>
>
>
> We had a great Virtual Lab Meeting today. One of the outcomes is that we
> are planning to restart the VLMs. The first one will be on July 27th at
> 11am EDT. Frances Weis-Garcia and Scott Brown will be discussing COVID-19
> serology assays. Click on the link below for the next speakers which have
> been scheduled for August and September. If you or someone you know has a
> topic to present, please add your name to the list for October, November or
> December. I will send out information for the call as we get closer to the
> date.
>
>
>
https://docs.google.com/spreadsheets/d/1dDiEGT3ImKbO6pZ8R29HX7Z4sG7QHEuecof7gf7ig3g/edit?usp=sharing
>
>
>
> On Thu, Jun 25, 2020 at 8:55 AM Christensen, Kurt Richard <
> <email obscured>>
> wrote:
>
> > Hi All,
> > I would be interested also.
> > Thanks,
> > Kurt
> >
> > Kurt Christensen
> > Lab Manager, Protein and Monoclonal Antibody Production Shared Resource
> > Baylor College of Medicine
> > Dan L. Duncan Cancer Center
> > Mail Stop BCM130, Rm R551E
> > 1 Baylor Plaza
> > Houston, TX 77030
> > Office: 713-798-2325
> > Lab:713-798-2327
> > Email: <email obscured>
> > Web:
> >
>
>
https://www.bcm.edu/centers/cancer-center/research/shared-resources/antibody-based-proteomics/recombinant-protein-monoclonal-antibody
> > iLab Service Requests:
> > https://bcm.corefacilities.org/account/login
> > iLab FAQs:
> >
> >
>
>
https://www.bcm.edu/research/advanced-technology-core-labs/lab-listing/ilanfaq/ilabfaqcustomer
> >
> > -----Original Message-----
> > From: Antibody Discussion Forum <email obscured>> On Behalf Of
> > David Blum
> > Sent: Wednesday, June 24, 2020 8:24 PM
> > To: <email obscured>
> > Subject: Re: [ABRF Ab Forum] FW: [EXT] Re: [core rigor and
> reproducibility
> > (corre)] We have an RRID number
> >
> > I sent out an email with the Zoom details and can add anybody else that
> > responds to this thread.
> >
> > On Wed, Jun 24, 2020 at 8:04 PM Greenfield, Edward A.,Ph.D. <
> > <email obscured>> wrote:
> >
> > > I would be interested.
> > >
> > > Best,
> > > Ed.
> > >
> > > -----Original Message-----
> > > From: Antibody Discussion Forum <email obscured>> On Behalf Of
> > > David Blum
> > > Sent: Wednesday, June 24, 2020 4:15 PM
> > > To: <email obscured>
> > > Subject: Re: [ABRF Ab Forum] FW: [EXT] Re: [core rigor and
> > > reproducibility (corre)] We have an RRID number
> > >
> > > External Email - Use Caution
> > >
> > > Laura,
> > >
> > > Thanks for the note. As a group, we haven't been active, but one
> > > thing we did was the Virtual Lab Meeting (VLM). I would be happy to
> > > setup a zoom teleconference and anyone that would like to join could.
> > > Perhaps the first call could be for strategic planning, discussing
> > > what we would like to accomplish then setup subsequent calls after
> > > that. Previously the calls were held at 11am EDT to accommodate people
> > in Europe and on the West coast.
> > >
> > > Would anyone be interested in me setting up a call next Monday June
> > > 29th at 11am EDT?
> > >
> > > On Tue, Jun 23, 2020 at 10:12 PM Bover,Laura <email obscured>>
> > > wrote:
> > >
> > > > Dear antibody guys,
> > > > I hope all of you are doing fine.
> > > > We are back in business since June 16th. Not sure for how long
> > > > because Texas is raising in cases: today, Gov. Greg Abbott shared
> > > > that Texas has seen 5,000 new coronavirus cases in a single day for
> > > > the first time, the numbers are moving fast in the wrong direction.
> > > > Our lab works, as probably yours, based on NCI funds and program
> > income.
> > > > Thus, as far as we can continue to work we are fine.
> > > >
> > > > On the other hand, this virus has made a breakthrough: everybody
> > > > realize that immune system exists, and everybody wants antibodies
> > > > against everything. People that never work in antibodies titration
> > > > before are titrating antibodies in plasma from recovered patients
> > > > and publishing a Preprint with one of the main figures a graph of an
> > > > ELISA!! Things that we usually only mention in Mat an Meth.
> > > >
> > > > With all that said I proposed Frances, if you would like to meet,
> > > > once a month or once in a time, and see how are all you doing, how
> > > > this is progressing and if you have contingencies plans in case you
> > > > cannot work. Or simple share a good moment, or news or papers, being
> > > > the case that one of the main treatments is so far convalescent
> > > > plasma and hyperimmune polyclonal antibodies obtained and purified
> > > > from horses, recombinant from llamas and eventually cloned from
> > > > single B cells from recovered donors to use as poolsof antibodies.
> > > >
> > > > Approaches for vaccines developments. In fact all things that we are
> > > > the experts! Immunizing to get immune response!
> > > > May be write a review, talk , etc?
> > > >
> > > > Also I would like to know in a personal question is, how would my
> > > > lab get a CLIA certification for making an ELISA for antibodies
> > > > titration in this case, instead than a researcher that never worked
> > > > with this, takes it as a potential result that may affect other's
> > lives.
> > > >
> > > > What do you think?
> > > > Can we do anything as a community of experts??
> > > > Thanks!!
> > > >
> > > > Laura
> > > > PS I would love to use zoom for these meetings and I am still
> > > > thinking why the heck I didn't invest in Zoom's stocks!!
> > > >
> > > > Laura Bover, PhD
> > > > Professor
> > > > Director Monoclonal Antibody Core Facility University of Texas
> > > > M.D.Anderson Cancer Center Associate member of The University of
> > > > Texas Graduate School of Biomedical Sciences at Houston Member of
> > > > the Scientific Review Committee 2 (former Clinical Research
> > > > Committee 2) Member of the Steering Committee of the Immunology
> > > > Program GSBS Immunology Department/ Genomics Medicine Department
> > > > 7455 Fannin St Room 1SCR4.2021
> > > > Houston- TX 77054
> > > > T 713-563-3301 <tel:713-563-3301>
> > > > F 713-563-3276 <tel:713-563-3276>
> > > > <email obscured>
> > > >
> > > > In order to continue obtaining Core support in a challenging
> > > > environment, it is crucial that our users acknowledge the following
> > > > grants in all publications (see following text). Thank you!
> > > > βWe acknowledge the UT-MDACC Monoclonal Antibodies Core facility,
> > > > supported in part by CCSG grant number P30 CA016672.β
> > > >
> > > >
> > > >
> > > >
> > > >
> > > > ο»ΏOn 6/23/20, 2:11 PM, "Frances Weis-Garcia" <
> > > > <email obscured>> wrote:
> > > >
> > > > WARNING: This email originated from outside of MD Anderson.
> > > > Please validate the sender's email address before clicking on links
> > > > or attachments as they may not be safe.
> > > >
> > > > I would love a monthly pow wow.
> > > > Please post to the list ... and let's see who is game. It think
> > > > you get a few takers.
> > > >
> > > >
> > > > On 6/23/20, 1:07 PM, "Bover,Laura" <email obscured>>
> wrote:
> > > >
> > > > Hi Frances, I have just seen this email hidden under 200! I
> > > > will read it and I will probably go ask with questions.
> > > > Should we organize a monthly meeting for MAbs group? Just to
> > > > exchange situations in other Cores and states and cities and
> > > institutions?
> > > >
> > > > One thing, I would like to know how a Core can have a
> > > > certification CLIA is it is developed an assay for diagnostic. Let's
> > > > say an ELISA, is that possible?
> > > > Thanks!
> > > > Laura
> > > >
> > > > On 6/2/20, 10:52 AM, "Core Rigor and Reproducibility (CoRRe)
> > > > on behalf of Frances Weis-Garcia" <email obscured> on behalf of
> > > > <email obscured>> wrote:
> > > >
> > > > WARNING: This email originated from outside of MD
> Anderson.
> > > > Please validate the sender's email address before clicking on links
> > > > or attachments as they may not be safe.
> > > >
> > > > β 1 file link β
> > > >
> > > > Found quite a few have been given for a few at MSKCC β¦
> > > > for example.
> > > >
> > > >
> > > >
> > > > * SCR_017850<
> > > > https://urldefense.com/v3/__https://scicrunch.org/resources/Any/sear
> > > > ch
> > > > ?q=SCR_017850&l=SCR_017850__;!!PfbeBCCAmug!zp7khhc7NG1GfdpdSbJxcD65l
> > > > I9 i3lotEEL46o4XMF7Xe17We2_0sMhA716G-kwD$
> > > > > - Molecular Cytogenetics Core Facility
> > > > * SCR_017691<
> > > > https://urldefense.com/v3/__https://scicrunch.org/resources/Any/sear
> > > > ch
> > > > ?q=SCR_017691&l=SCR_017691__;!!PfbeBCCAmug!zp7khhc7NG1GfdpdSbJxcD65l
> > > > I9 i3lotEEL46o4XMF7Xe17We2_0sMhA7_em4O2l$
> > > > > - Antibody & Bioresource Core Facility
> > > > * SCR_017853<
> > > > https://urldefense.com/v3/__https://scicrunch.org/resources/Any/sear
> > > > ch
> > > > ?q=SCR_017853&l=SCR_017853__;!!PfbeBCCAmug!zp7khhc7NG1GfdpdSbJxcD65l
> > > > I9 i3lotEEL46o4XMF7Xe17We2_0sMhA79oyOBYh$
> > > > > - Investigational Products Support Core Facility
> > > >
> > > > From: Frances Weis-Garcia <
> <email obscured>
> > >
> > > > Date: Tuesday, June 2, 2020 at 11:48 AM
> > > > To: "Core Rigor and Reproducibility (CoRRe)" <
> > > > <email obscured>>
> > > > Subject: We have an RRID number
> > > >
> > > > We have an RRID number
> > > > But cannot find other cores with RRID numbers (yet)
> > > >
> > > > Only matters if we want to define the structure of the
> > > > core RRID
> > > >
> > > > [A screenshot of a cell phone Description automatically
> > > > generated]
> > > >
> > > > β 1 file β
> > > >
> > > > β‘ image001.png (386kb)
> > > >
> > > > https://urldefense.com/v3/__http://list.abrf.org/r/file/61rKfXKRRhmc
> > > > eb
> > > > jVxMqaDd73I7M-1CvB-2NFYRPN/__;!!PfbeBCCAmug!zp7khhc7NG1GfdpdSbJxcD65
> > > > lI 9i3lotEEL46o4XMF7Xe17We2_0sMhA7-cq3rnW$
> > > >
> > > > ββ
> > > > View topic
> > > >
> > > https://urldefense.com/v3/__http://list.abrf.org/r/topic/5kRaozb5cnXRg
> > > NPMB40Ica__;!!PfbeBCCAmug!zp7khhc7NG1GfdpdSbJxcD65lI9i3lotEEL46o4XMF7X
> > > e17We2_0sMhA77Xsei7H$
> > > > Leave group
> > > > <email obscured>?Subject=Unsubscribe
> > > >
> > > >
> > > >
> > > >
> > > > The information contained in this e-mail message may be
> > > > privileged, confidential, and/or protected from disclosure. This
> > > > e-mail message may contain protected health information (PHI);
> > > > dissemination of PHI should comply with applicable federal and state
> > > > laws. If you are not the intended recipient, or an authorized
> > > > representative of the intended recipient, any further review,
> > > > disclosure, use, dissemination, distribution, or copying of this
> > > > message or any attachment (or the information contained therein) is
> > > > strictly prohibited. If you think that you have received this e-mail
> > > > message in error, please notify the sender by return e-mail and
> > > > delete all references to it and its contents from your systems.
> > > >
> > > >
> > > >
> > > >
> > > > The information contained in this e-mail message may be privileged,
> > > > confidential, and/or protected from disclosure. This e-mail message
> > > > may contain protected health information (PHI); dissemination of PHI
> > > > should comply with applicable federal and state laws. If you are not
> > > > the intended recipient, or an authorized representative of the
> > > > intended recipient, any further review, disclosure, use,
> > > > dissemination, distribution, or copying of this message or any
> > > > attachment (or the information contained therein) is strictly
> > > > prohibited. If you think that you have received this e-mail message
> > > > in error, please notify the sender by return e-mail and delete all
> > > references to it and its contents from your systems.
> > > >
> > > > ββ
> > > > View topic
> > > > https://urldefense.proofpoint.com/v2/url?u=http-3A__list.abrf.org_r_
> > > > topic_5bRUHLyrqMfdch3xJ1egAo&d=DwIFaQ&c=ZQs-KZ8oxEw0p81sqgiaRA&r=_dq
> > > > qB8TU9vN7Hm15OCeZVQ&m=1u0JscGdrLmtrkHhrqe8WwI6NVzgutPR30s1tgjyY_Y&s=
> > > > cfvvDUSfzl7P5FUstOu5spgTWua1wjQtUjDEvRIihyY&e=
> > > > Leave group <email obscured>?Subject=Unsubscribe
> > > >
> > > >
> > >
> > > ββ
> > > View topic
> > > https://urldefense.proofpoint.com/v2/url?u=http-3A__list.abrf.org_r_to
> > > pic_7efFJlkEa5AdocqXi4oNC2&d=DwIFaQ&c=ZQs-KZ8oxEw0p81sqgiaRA&r=_dqqB8T
> > > U9vN7Hm15OCeZVQ&m=1u0JscGdrLmtrkHhrqe8WwI6NVzgutPR30s1tgjyY_Y&s=LmYnYw
> > > s_n3DWZpvKTJ2P451Erv9uVBK1pmDmRUMZom0&e=
> > > Leave group <email obscured>?Subject=Unsubscribe
> > >
> > >
> > >
> > > The information in this e-mail is intended only for the person to whom
> > > it is addressed. If you believe this e-mail was sent to you in error
> > > and the e-mail contains patient information, please contact the
> > > Partners Compliance HelpLine at
> > > https://urldefense.proofpoint.com/v2/url?u=http-3A__www.partners.org_c
> > > omplianceline&d=DwIFaQ&c=ZQs-KZ8oxEw0p81sqgiaRA&r=_dqqB8TU9vN7Hm15OCeZ
> > > VQ&m=1u0JscGdrLmtrkHhrqe8WwI6NVzgutPR30s1tgjyY_Y&s=xEjGmVKK9e2U9jBhm1F
> > > sF8s2Ci7jdURmLIHNXlgfHas&e= . If the e-mail was sent to you in error
> > > but does not contain patient information, please contact the sender and
> > properly dispose of the e-mail.
> > >
> > > ββ
> > > View topic
> > > https://urldefense.proofpoint.com/v2/url?u=http-3A__list.abrf.org_r_to
> > > pic_seIYKRgv7RlwME9A9WyC9&d=DwIFaQ&c=ZQs-KZ8oxEw0p81sqgiaRA&r=_dqqB8TU
> > > 9vN7Hm15OCeZVQ&m=1u0JscGdrLmtrkHhrqe8WwI6NVzgutPR30s1tgjyY_Y&s=ipzGFUu
> > > ScZyavm7S0h3zU_9sgQ9wOgARsOdia3nq0Dg&e=
> > > Leave group <email obscured>?Subject=Unsubscribe
> > >
> > >
> >
> > ββ
> > View topic
> >
>
>
https://urldefense.proofpoint.com/v2/url?u=http-3A__list.abrf.org_r_topic_5UDVSZ9IKBgdxohmZxQlwi&d=DwIFaQ&c=ZQs-KZ8oxEw0p81sqgiaRA&r=_dqqB8TU9vN7Hm15OCeZVQ&m=1u0JscGdrLmtrkHhrqe8WwI6NVzgutPR30s1tgjyY_Y&s=XqcTqNOsaS3jiPdGxRPjUKa7BkHkAbJbJq77y8s5hK0&e=
> > Leave group <email obscured>?Subject=Unsubscribe
> >
> >
> > ββ
> > View topic http://list.abrf.org/r/topic/4g1Itq5NXiJN4aUBJ5jS2c
> > Leave group <email obscured>?Subject=Unsubscribe
> >
> >
>
> ββ
> View topic http://list.abrf.org/r/topic/38fuvH6jA6ZRysO36ljktx
> Leave group <email obscured>?Subject=Unsubscribe
>
> ββ
> View topic http://list.abrf.org/r/topic/4LtTs7Ti94j8FpMxpagEtY
> Leave group <email obscured>?Subject=Unsubscribe
>
>
